- Previous Close
0.3087 - Open
0.2984 - Bid --
- Ask --
- Day's Range
0.2984 - 0.2984 - 52 Week Range
0.2000 - 0.3763 - Volume
2,034 - Avg. Volume
0 - Market Cap (intraday)
76.482M - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
14.92 - EPS (TTM)
0.0200 - Earnings Date Aug 10, 2024 - Aug 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 6, 2022
- 1y Target Est
--
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It offers cord blood, cord lining, and cord tissue banking services, including processing and storage of stem cells; and various diagnostics services, such as newborn genetic screening, pediatric vision and ear screening, pediatric allergen test, genetic talent test, preimplantation genetic screening, endometrial receptivity test, non-invasive prenatal testing, and newborn metabolic screening. The company also provides Moms Up, a mobile app for pregnancy and parenting resources for moms and moms-to-be. In addition, it provides medical laboratory, marketing, and property investment services. Cordlife Group Limited was incorporated in 2001 and is headquartered in Singapore.
www.cordlife.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CLIFF
Performance Overview: CLIFF
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLIFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLIFF
Valuation Measures
Market Cap
28.79M
Enterprise Value
-16.66M
Trailing P/E
19.65
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.79
Price/Book (mrq)
0.76
Enterprise Value/Revenue
0.18
Enterprise Value/EBITDA
1.04
Financial Highlights
Profitability and Income Statement
Profit Margin
6.32%
Return on Assets (ttm)
-0.12%
Return on Equity (ttm)
2.64%
Revenue (ttm)
55.73M
Net Income Avi to Common (ttm)
3.52M
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
66.02M
Total Debt/Equity (mrq)
2.58%
Levered Free Cash Flow (ttm)
7.81M